Arbutus Biopharma (NASDAQ: ABUS) reported second-quarter earnings that missed analyst expectations on profitability while exceeding revenue forecasts. The biopharmaceutical company logged a quarterly loss of $(0.03) per share, which missed the consensus estimate of $(0.02) by 50 percent. This result marks a significant deterioration from the same period last year, representing a 400 percent decrease from earnings of $0.01 per share.

Despite the miss on earnings per share, the company’s top-line performance surpassed market expectations. Arbutus reported quarterly sales of $1.014 million, beating the analyst consensus estimate of $700,000 by 44.86 percent. However, the revenue figure reflects a substantial year-over-year contraction, falling 90.56 percent from sales of $10.739 million in the corresponding quarter of the previous year.

What the Numbers Show

The divergence between the revenue beat and the earnings miss highlights the pressure on Arbutus Biopharma’s cost structure relative to its shrinking top line. While sales exceeded the modest $700,000 expectation, the absolute revenue level of $1.014 million is a fraction of the $10.739 million generated a year ago. This 90.56 percent revenue decline suggests that fixed costs or operational expenditures did not decrease proportionally with the drop in sales, contributing to the widened loss per share compared to the prior year’s profit of $0.01.

Arbutus Biopharma Corporation and its exclusive licensee Genevant Sciences GmbH have filed three international lawsuits seeking to enforce patents protecting their lipid nanoparticle (LNP) technology against Pfizer Inc., BioNTech SE, and certain of their affiliates. The actions seek monetary relief and injunctions against Pfizer/BioNTech’s mRNA-LNP COVID-19 vaccines and other infringing products. This legal expansion follows an ongoing enforcement proceeding in the U.S. District Court for the District of New Jersey regarding five U.S. patents.

The filings include a case in the Federal Court of Canada (File No. T-3200-26) targeting Canadian Patent No. 2,721,333, and two actions in the Unified Patent Court (UPC). The UPC cases, numbered PR-UPC-CFI-0002562/2026 and PR-UPC-CFI-0002566/2026, assert European patents EP 4 241 767 and EP 4 495 237 respectively. The UPC actions seek relief across multiple European jurisdictions, including Austria, Belgium, France, Germany, Italy, Spain, and Sweden.

Separately, Arbutus announced the receipt of approximately $178M from Moderna Inc. on July 8, 2026. This payment represents Arbutus’ share of a noncontingent payment under a March 2026 settlement agreement resolving global patent infringement litigation related to Moderna’s COVID-19 vaccines. The amount includes reimbursement of Arbutus’ litigation costs as per its license agreement with Genevant.

Arbutus also expects to receive a dividend from Genevant’s parent in Q3 2026, stemming from its ownership of approximately 16% of Genevant’s parent’s outstanding common equity. Following this anticipated receipt, the company plans to return up to approximately $230M in capital to shareholders. The capital return program, subject to board approval, may utilize methods such as a tender offer, open market purchases, or accelerated share repurchases.

Legal Filings Overview